Sansero Life Sciences Announces Joint Study With the University of Toronto to Advance Clinical Research of Psychedelic Medications
Ryan Allway
October 2nd, 2020
Psychedelics
Sansero Life Sciences, a leader in the development of psilocybin-based medicines, announced today that it has partnered with the University of Toronto to complete a preclinical study on the effects of low-dose psilocybin. The study will bring new scientific understanding to psilocybin metabolism in the mammalian body and how low-dose psilocybin affects mental health conditions such as depression and anxiety.
The research agreement between Sansero and the University of Toronto is an important step in expanding the company’s pharmaceutical product development program. Sansero is focused on developing pharmaceuticals that include a minimal effective dose (MED) of psilocybin in combination with other naturally-sourced ingredients. Sansero’s MED approach is directed to establishing a new product category that provides therapeutic benefits of psilocybin without the psychoactive effects of a flood dose.
“Our goal is to make psilocybin-based medications accessible to people who could benefit from the potentially life-changing effects of psilocybin — including people who are motivated to avoid the psychoactive effects of a flood dose,” explains Dr. Darryl Hudson, Sansero’s Chief Science Officer. “We are excited to work with the University of Toronto on this preclinical study, which will provide valuable insight into how low-doses of psilocybin can be combined effectively with additional pharmaceutical ingredients. Scientific discovery is based on collaboration, and with the University’s expert researchers working hand in hand with our lab, we can expedite development, bringing these pharmaceuticals to market in Canada and internationally as quickly as possible. For a variety of reasons, mental health is becoming a higher priority than ever before and we have confidence that the MED approach with psilocybin will bring further promising results.”
“The University’s partnership with Sansero in this preclinical study is important to deepening our knowledge of psilocybin,” said Professor Richard Bazinet of the University of Toronto’s Department of Nutritional Sciences. “Led by Dr. Adam Metherel, this study will contribute to the University’s knowledge base for a new generation of scientists as we map the metabolism and further explore the compound’s behavioral effects.”
About Sansero Life Sciences
Sansero Life Sciences is a leader in compliant cultivation, formulation, research and development of psilocybin-based therapeutic products. Sansero’s executive and advisory team has over 35 years of combined clinical and research experience in plant and human genetics, biochemistry, molecular biology and tissue culture, and over 15 years of experience developing proprietary and stable plant genetics. Sansero is dedicated to discovering natural therapies for neurological disorders and mental health conditions.
About the University of Toronto (U of T)
Founded in 1827, the University of Toronto is Canada’s leading institution of learning, discovery and knowledge. U of T is one of the world’s leading research-intensive universities, with significant impact both locally and globally. Our outstanding research scholars are committed to understanding and solving the global challenges that face us today – and generating new possibilities for the future.
View source version on businesswire.com:https://www.businesswire.com/news/home/20201001005275/en/
Contacts
Corey Herscu for Sansero Life Sciences
corey@verbfactory.com
(416) 300-3030
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Matthew Nordgren is an ambitious executive, dedicated philanthropist, and accomplished athlete who brings a unique passion to creating strategic alliances. He has breadth and depth of experience in finance, corporate development, and capital sourcing, as well as in building highly motivated teams of skilled professionals. In 2005, Mr. Nordgren received his education at the University […]
The producers of O’ Cannabiz have decades of experience producing national-profile events and creating global connections between business communities in the arts, broadcasting, media and technology. They have organized trade summit initiatives with governments around the world. And they have worked closely with sponsors in all levels of Canadian government.
Nabis Holdings is a Canadian investment issuer that invests in high quality cash flowing assets across multiple industries, including real property, securities, cryptocurrency, and all aspects of the U.S. and international cannabis sector.
Headquartered in Lakewood, Colo., STWC Holdings is a complete ecosystem of entities and services that support the burgeoning cannabis industry.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
